Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q2 FY26 results · Jul–Sep 2025
Ajanta Pharma reported revenue from operations of ₹1,353.73 crore (up 14.1% from Q2 FY25) and net profit of ₹260.19 crore (up 20.2% from Q2 FY25) for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,353.73 | 1,186.64 | +14.1% | 1,302.65 | +3.9% |
| Other income | 59.34 | 19.48 | +204.6% | 26.33 | +125.4% |
| Total income | 1,413.07 | 1,206.12 | +17.2% | 1,328.98 | +6.3% |
| Profit before tax | 340.81 | 290.24 | +17.4% | 331.13 | +2.9% |
| Net profit for the period | 260.19 | 216.48 | +20.2% | 255.34 | +1.9% |
| EPS, basic (₹) | 20.83 | 17.27 | +20.6% | 20.44 | +1.9% |
| Net margin (%) | 19.2 | 18.2 | 19.6 |
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,220.24 | 1,128.91 | +8.1% | 1,208.56 | +1.0% |
| Other income | 75.03 | 40.34 | +86.0% | 40.63 | +84.7% |
| Total income | 1,295.27 | 1,169.25 | +10.8% | 1,249.19 | +3.7% |
| Profit before tax | 321.97 | 309.20 | +4.1% | 328.99 | −2.1% |
| Net profit for the period | 249.53 | 234.98 | +6.2% | 254.97 | −2.1% |
| EPS, basic (₹) | 19.98 | 18.75 | +6.6% | 20.41 | −2.1% |
| Net margin (%) | 20.4 | 20.8 | 21.1 |
Consolidated
- Filed with BSE
- 03 Nov 2025, 16:49 IST
- Board meeting
- 03 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Nov 2025, 16:49 IST
- Board meeting
- 03 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE